Effect of angiotensin receptor neprilysin inhibitor on physical activity in patients with heart failure with reduced ejection fraction, monitored by implantable electronic device home monitoring.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
23 Jan 2024
23 Jan 2024
Historique:
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
22
1
2024
Statut:
aheadofprint
Résumé
Angiotensin receptor neprilysin inhibitor (ARNI) therapy is a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF), with significant improvement in mortality as well as morbidity and quality of life. However, maximal ARNI doses often result in hypotension. Recent studies with 'real world' experience suggest that lower doses of ARNI are as effective as higher doses.In order to evaluate the symptomatic effect of low-dose ARNI in HFrEF patients, we analyzed physical activity data obtained via home monitoring of patients with cardiac implantable electronic devices (CIEDs). We retrospectively analyzed physical activity data obtained from HFrEF patients with CIED-active home monitoring during the years 2021-2022. Patients with ARNI therapy were further divided into subgroups according to the administered dose. Low-dose ARNI included doses of up to 24/26 mg sacubitril/valsartan daily. Intermediate dose and high dose included doses of 72/78-120/130 mg/day, and 144/156-194/206 mg/day, respectively. A total of 122 patients had home monitoring-compatible CIEDs and HFrEF during the study period. Sixty-four of these patients were treated with ARNI. Administration of low-dose ARNI resulted in a 20% increase in daily activity when compared with patients without ARNI treatment (P = 0.038). Change in physical activity of patients in the intermediate-dose and high-dose groups was not significant. Younger patients, patients with cardiac resynchronization therapy, and patients without diabetes mellitus were more physically active. Low-dose ARNI had a beneficial effect on physical activity in HFrEF patients. MH via CIED provided real-life objective data for patients' follow-up.
Identifiants
pubmed: 38251452
doi: 10.2459/JCM.0000000000001595
pii: 01244665-990000000-00180
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599–3726.
Van Riet EES, Hoes AW, Wagenaar KP, Limburg A, Landman MAJ, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time: a systematic review. Eur J Heart Fail 2016; 18:242–252.
Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res 2021; 128:1421–1434.
Giallauria F, Piccioli L, Vitale G, Sarullo FM. Exercise training in patients with chronic heart failure: a new challenge for Cardiac Rehabilitation Community. Monaldi Arch Chest Dis 2018; 88:38–44.
Klompstra L, Kyriakou M, Lambrinou E, et al. Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021; 23:83–91.
Fuentes-Abolafio IJ, Stubbs B, Pérez-Belmonte LM, Bernal-López MR, Gómez-Huelgas R, Cuesta-Vargas AI. Physical functional performance and prognosis in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2020; 20:1–23.
Wu LH, Wang CH, Liu MH, Hsu CC, Yuan PH, Fu TC. Factors associated with participation rate and predictive of improvement after cardiac rehabilitation in patients with heart failure. J Cardiopulm Rehabil Prev 2023; 43:49–54.
Gerow R, Altice N, Wu Y, Muthukattil R, Carter KF. Early cardiac rehabilitation to reduce heart failure readmissions. J Cardiopulm Rehabil Prev 2022; 42:324–330.
Chandra A, Lewis EF, Claggett BL, et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol 2018; 3:498–505.
Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 76:2379–2390.
Guazzi M, Dickstein K, Vicenzi M, Arena R. Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail 2009; 2:549–555.
Rosman L, Lampert R, Sears SF, Burg MM. Measuring physical activity with implanted cardiac devices: a systematic review. J Am Heart Assoc 2018; 7 (11):
McMurray JJ, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79:1757–1780.
John J.V. McMurray, M.D., Milton Packer, M.D., Akshay S. Desai, M.D., M.P.H., Jianjian Gong, Ph.D., Martin P. Lefkowitz, M.D., Adel R. Rizkala, Pharm.D., Jean L. Rouleau, M.D., Victor C. Shi, M.D., Scott D. Solomon, M.D., Karl Swedberg, M.D., Ph.D., and M for the PHI and C. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014; 371(11):993-1004. doi:DOI: 10.1056/NEJMoa1409077.
Vitale G, Romano G, Di Franco A, et al. Early effects of sacubitril/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction. J Clin Med 2019; 8:262.
Lau CW, Martens P, Lambeets S, Dupont M, Mullens W. Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients. Acta Cardiol 2019; 74:405–412.
Vardeny O, Claggett B, Packer M, et al. Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail 2016; 18:1228–1234.
Mohebi R, Liu Y, Piña IL, et al. Dose-response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2022; 80:1529–1541.
Kim H, Oh J, Lee S, et al. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Sci Rep 2021; 11:16335.
Marzec L, Raghavan Id S, Banaei-Kashani F, et al. Device-measured physical activity data for classification of patients with ventricular arrhythmia events: a pilot investigation. PLoS One 2018; 13:e0206153.
Roberts DH, Baxter SE, Brennan PT, Gammage MD. Comparison of externally strapped versus implanted accelerometer- or vibration-based rate adaptive pacemakers during various physical activities. Pacing Clin Electrophysiol 1995; 18 (1 pt 1):65–69.
Leung SK, Lau CP, Tang MO, Leung Z. New integrated sensor pacemaker: comparison of rate responses between an integrated minute ventilation and activity sensor and single sensor modes during exercise and daily activities and nonphysiological interference. Pacing Clin Electrophysiol 1996; 19 (11 pt 2):1664–1671.
McAlister HF, Soberman J, Klementowicz P, Andrews C, Furman S. Treadmill assessment of an activity-modulated pacemaker: the importance of individual programming. Pacing Clin Electrophysiol 1989; 12:486–500.
Padeletti L, Pieragnoli P, Di Biase L, et al. Is a dual-sensor pacemaker appropriate in patients with sino-atrial disease? Results from the DUSISLOG study. Pacing Clin Electrophysiol 2006; 29:34–40.
R Core Team (2023). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https://www.R-project.org/. 2023. [Accessed - 2023]
Venables WN, Ripley BD. Modern applied statistics with S. Fourth edition. New York:Springer; 2002.
Malfatto G, Ravaro S, Caravita S, et al. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test. Acta Cardiol 2020; 75:732–736.
Corrado E, Dattilo G, Coppola G, et al. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. Eur J Clin Pharmacol 2022; 78:19.
Piepoli MF, Hussain RI, Comin-Colet J, et al. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail 2021; 23:127–135.
Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012; 126:1858–1868.
Kraai IH, Vermeulen KM, Luttik MLA, Hoekstra T, Jaarsma T, Hillege HL. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail 2013; 15:1113–1121.
Nandal S, Chow CL, Hannah V, Vaddadi G, Van Gaal W. Tolerability and efficacy of sacubitril/valsartan in clinical practice. Intern Med J 2021; 51:87–92.
Visco V, Radano I, Campanile A, et al. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. ESC Heart Fail 2022; 9:2909–2917.
Nordberg Backelin C, Fu M, Ljungman C. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting. ESC Heart Fail 2020; 7:1049–1055.
Martens P, Verluyten L, Van de Broek H, et al. Determinants of maximal dose titration of sacubitril/valsartan in clinical practice. Acta Cardiol 2021; 76:20–29.